



Figure S1. PCSK9 and platelet activation. Platelet aggregation (**A**) with relative representative tracing (**B**) and platelet TxB₂ (**C**) evaluated in platelet rich plasma (PRP) treated with anti-CD36, anti-LOX1, Nox2ds-tat and anti-PCSK9 in absence of PCSK9 and stimulated with STC of collagen (0.25 $\mu\text{g}/\text{mL}$) ($n = 5$) ($p = \text{ns}$ for paired analyses).